Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea.

Skinmed

Volumn 6, Issue 5, 2007, Pages 221-226

  Theobald, Klaus ^a   Bradshaw, Mark ^a   Leyden, James ^a  

^a Managed Care and Professional Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DOXYCYCLINE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOSE RESPONSE; HUMAN; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; ROSACEA; STATISTICAL MODEL;

ANTI-INFLAMMATORY AGENTS; AREA UNDER CURVE; CLINICAL TRIALS, PHASE I; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; HUMANS; LINEAR MODELS; ROSACEA;

EID: 35348892022     PISSN: 15409740     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-9740.2007.06460.x     Document Type: Article

References (0)